{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:03:22Z","timestamp":1785506602525,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11523-026-01223-2","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:47:30Z","timestamp":1779274050000},"page":"549-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-7543","authenticated-orcid":false,"given":"Yu","family":"Sunakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kyogoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Yanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"3","key":"1223_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1223_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102023","author":"G Martini","year":"2020","unstructured":"Martini G, Ciardiello D, Vitiello PP, et al. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed? Cancer Treat Rev. 2020. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102023.","journal-title":"Cancer Treat Rev"},{"issue":"10449","key":"1223_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","volume":"404","author":"C Eng","year":"2024","unstructured":"Eng C, Yoshino T, Ru\u00edz-Garc\u00eda E, et al. Colorectal cancer. Lancet. 2024;404(10449):294\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(24)00360-X.","journal-title":"Lancet"},{"issue":"5","key":"1223_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0.","journal-title":"Lancet Oncol"},{"key":"1223_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051330","author":"R Giampieri","year":"2020","unstructured":"Giampieri R, Ziranu P, Daniele B, et al. From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): circulating predictive biomarkers to anti-VEGFR therapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12051330.","journal-title":"Cancers (Basel)"},{"key":"1223_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637823","volume":"11","author":"E Lai","year":"2021","unstructured":"Lai E, Cascinu S, Scartozzi M. Are all anti-angiogenic drugs the same in the treatment of second-line metastatic colorectal cancer? Expert opinion on clinical practice. Front Oncol. 2021;11:637823. https:\/\/doi.org\/10.3389\/fonc.2021.637823.","journal-title":"Front Oncol"},{"issue":"3","key":"1223_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/annonc\/mdx767","volume":"29","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hozak RR, Yoshino T, et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol. 2018;29(3):602\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx767.","journal-title":"Ann Oncol"},{"key":"1223_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2019.10.026","volume":"127","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Muro K, Cunningham D, et al. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020;127:150\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.026.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1223_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. npj Precis Oncol. 2025;9(1):84. https:\/\/doi.org\/10.1038\/s41698-025-00876-y.","journal-title":"npj Precis Oncol"},{"key":"1223_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102999","author":"A Holz","year":"2025","unstructured":"Holz A, Paul B, Zapf A, et al. Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: a systematic review and meta-analysis. Cancer Treat Rev. 2025. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102999.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1223_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini C, Rossini D, Dell\u2019Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343\u201350. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5080.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1223_CR12","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01886-0.","journal-title":"Nat Med"},{"issue":"5","key":"1223_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101636","volume":"8","author":"H Yasui","year":"2023","unstructured":"Yasui H, Okita Y, Nakamura M, et al. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. ESMO Open. 2023;8(5):101636. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101636.","journal-title":"ESMO Open"},{"issue":"1","key":"1223_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/cdli.10.1.133-139.2003","volume":"10","author":"W de Jager","year":"2003","unstructured":"de Jager W, te Velthuis H, Prakken BJ, et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10(1):133\u20139. https:\/\/doi.org\/10.1128\/cdli.10.1.133-139.2003.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"4","key":"1223_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00280-003-0572-5","volume":"51","author":"KA Keyes","year":"2003","unstructured":"Keyes KA, Mann L, Cox K, et al. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol. 2003;51(4):321\u20137. https:\/\/doi.org\/10.1007\/s00280-003-0572-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7404","key":"1223_CR16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532\u20136. https:\/\/doi.org\/10.1038\/nature11156.","journal-title":"Nature"},{"issue":"7404","key":"1223_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr.","year":"2012","unstructured":"Diaz LA Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537\u201340. https:\/\/doi.org\/10.1038\/nature11219.","journal-title":"Nature"},{"issue":"7","key":"1223_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795\u2013801. https:\/\/doi.org\/10.1038\/nm.3870.","journal-title":"Nat Med"},{"issue":"29","key":"1223_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303740120","volume":"120","author":"K Hosaka","year":"2023","unstructured":"Hosaka K, Andersson P, Wu J, et al. KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas. Proc Natl Acad Sci U S A. 2023;120(29):e2303740120. https:\/\/doi.org\/10.1073\/pnas.2303740120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1223_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","volume":"6","author":"A Sparmann","year":"2004","unstructured":"Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6(5):447\u201358. https:\/\/doi.org\/10.1016\/j.ccr.2004.09.028.","journal-title":"Cancer Cell"},{"issue":"8","key":"1223_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/ijc.26164","volume":"130","author":"N Sunaga","year":"2012","unstructured":"Sunaga N, Imai H, Shimizu K, et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer. 2012;130(8):1733\u201344. https:\/\/doi.org\/10.1002\/ijc.26164.","journal-title":"Int J Cancer"},{"issue":"3","key":"1223_CR22","first-page":"887","volume":"62","author":"HJ Varghese","year":"2002","unstructured":"Varghese HJ, Davidson MTM, MacDonald IC, et al. Activated Ras regulates the proliferation\/apoptosis balance and early survival of developing micrometastases1. Cancer Res. 2002;62(3):887\u201391.","journal-title":"Cancer Res"},{"issue":"21","key":"1223_CR23","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1007\/s00018-013-1331-3","volume":"70","author":"A Bottos","year":"2013","unstructured":"Bottos A, Bardelli A. Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? Cell Mol Life Sci. 2013;70(21):4131\u201340. https:\/\/doi.org\/10.1007\/s00018-013-1331-3.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1223_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95345-4","volume":"11","author":"Y Lim","year":"2021","unstructured":"Lim Y, Kim S, Kang J-K, et al. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. Sci Rep. 2021;11(1):16333. https:\/\/doi.org\/10.1038\/s41598-021-95345-4.","journal-title":"Sci Rep"},{"issue":"7","key":"1223_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/bjc.2015.329","volume":"113","author":"D Lambrechts","year":"2015","unstructured":"Lambrechts D, Thienpont B, Thuillier V, et al. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer. 2015;113(7):1027\u201334. https:\/\/doi.org\/10.1038\/bjc.2015.329.","journal-title":"Br J Cancer"},{"key":"1223_CR26","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.2147\/cmar.S181570","volume":"10","author":"G Marisi","year":"2018","unstructured":"Marisi G, Scarpi E, Passardi A, et al. IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab. Cancer Manag Res. 2018;10:5659\u201366. https:\/\/doi.org\/10.2147\/cmar.S181570.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"1223_CR27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.Can-09-3965","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70(3):1063\u201371. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3965.","journal-title":"Cancer Res"},{"issue":"5089","key":"1223_CR28","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1126\/science.1281554","volume":"258","author":"AE Koch","year":"1992","unstructured":"Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258(5089):1798\u2013801. https:\/\/doi.org\/10.1126\/science.1281554.","journal-title":"Science"},{"issue":"12","key":"1223_CR29","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1091\/mbc.e07-01-0004","volume":"18","author":"ML Petreaca","year":"2007","unstructured":"Petreaca ML, Yao M, Liu Y, et al. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8\/CXCL8) is required for IL-8\/CXCL8-induced endothelial permeability. Mol Biol Cell. 2007;18(12):5014\u201323. https:\/\/doi.org\/10.1091\/mbc.e07-01-0004.","journal-title":"Mol Biol Cell"},{"issue":"36","key":"1223_CR30","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1038\/onc.2011.563","volume":"31","author":"R Bonavia","year":"2012","unstructured":"Bonavia R, Inda MM, Vandenberg S, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-\u03baB, interleukin-8 pathway. Oncogene. 2012;31(36):4054\u201366. https:\/\/doi.org\/10.1038\/onc.2011.563.","journal-title":"Oncogene"},{"issue":"1","key":"1223_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdy461","volume":"30","author":"T Yoshino","year":"2019","unstructured":"Yoshino T, Portnoy DC, Obermannov\u00e1 R, et al. Biomarker analysis beyond angiogenesis: RAS\/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE\u2014a global phase III study. Ann Oncol. 2019;30(1):124\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdy461.","journal-title":"Ann Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01223-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:17Z","timestamp":1785503717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01223-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01223-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yu Sunakawa has received honoraria from Eli Lilly Japan K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Astellas Pharma Inc., Sysmex, and Guardant Health; research funding from Chugai Pharmaceutical Co., Ltd., Taiho, Parexel International Inc., PRA Health Sciences, Inc., IQVIA Services Japan K.K., ICON Clinical Research, Amgen, Bristol-Myers Squibb K.K., Astellas Pharma Inc., and Takeda Pharmaceutical Co., Ltd.. Hiroyuki Takeda has received honoraria from Bristol-Myers Squibb K.K. and Guardant Health Japan. Satoshi Yuki\u00a0has received honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., MSD K.K., Bayer Yakuhin Ltd., Merck Biopharma Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Roche Diagnostics K.K., Nippon Boehringer Ingelheim Co., Ltd., and MIYARISAN Pharmaceutical Co., Ltd. Akihito Tsuji has received honoraria from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb K.K., Sanofi; research funding from Taiho Pharmaceutical Co., Ltd., Sanofi, Ono Pharmaceutical Co., Ltd. Hisateru Yasui, Manabu Shiozawa, Naoya Akazawa, Tamotsu Sagawa, Kazuhiro Shiraishi, Takahisa Kyogoku, Takashi Mine, Yasuhiro Yuasa, Takanori Watanabe, Tatsuya Kinjo, Yoshihiro Okita, Hiroyuki Okuyama, Koki Miyakawa, Ayana Kobara, Shoko Yanaka, Yukiko Abe, Wataru Ichikawa, and Masashi Fujii, declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board (IRB) of each participating site. Specifically, the IRB of Japan Clinical Cancer Research Organization approved the study on 24 October 2018. The study was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants for both study participation and publication of the results.","order":3,"name":"Ethics","label":"Consent to Participate and for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YS, HY, MS, HT, NA, TS, KS, TK, TM, YY, TW, TK, YO, HO, SY, WI, AT contributed to the investigation and writing\u2014review & editing. YS was responsible for conceptualization, investigation, writing\u2014original draft, writing\u2014review & editing, and funding acquisition. YS, TK, YO, HO, SY, WI handled data curation, methodology, formal analysis, and writing\u2014review & editing. MF took part in project administration, investigation, writing\u2014review & editing, and supervision.","order":6,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}